Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Zevra Therapeutics, Inc. reported revenue of $106M, up 350.9% year over year. Operating margin was -59.1% and net margin 78.2%, on a free-cash-flow margin of -2.3% with capital expenditure at 0.8% of revenue. Every figure is computed directly from ZVRA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $106M | -59.1% | 78.2% |
| FY2024 | $24M | -368.5% | -446.9% |
| FY2023 | $27M | -180.6% | -167.7% |
| FY2022 | $10M | -418.9% | -263.5% |
| FY2021 | $29M | 27.0% | -29.9% |
How does ZVRA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.